Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Hepatitis C; Chronic Clinical Trials

A listing of Hepatitis C; Chronic medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (69) clinical trials

Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

The purpose of this study is to assess the pharmacokinetics (PK), safety, and efficacy of MK-5172, a fixed dose combination (FDC) of elbasvir (EBR) and grazoprevir (GZR) in pediatric hepatitis C virus (HCV)-infected participants aged 3 years up to 18 years.

Phase

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients

The capacity to scale-up interferon-free DAA therapy would be enhanced by simplified treatment monitoring strategies. The "next generation" DAA regimen of glecaprevir (300mg)/pibrentasvir (120mg), a protease inhibitor and NS5A inhibitor, provides key features for HCV treatment simplification, including on-treatment monitoring: 1) pangenotypic activity with extremely high efficacy (SVR>95%); 2) no ...

Phase

Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence

Hepatitis C virus (HCV) is a preventable and curable blood-borne virus. Adherence to HCV therapies is essential to achieve sustained virologic response (SVR) or cure. New direct-acting agents (DAA) are now available, such as fixed-dose combination of ledipasvir and sofosbuvir, which is given once daily with or without ribavirin to ...

Phase N/A

Re-treatment of HCV Following DAA Failure

-Introduction Oral drugs, termed collectively as 'Direct-acting anti-viral agents' (DAAs), are the standard-of-care for HCV treatment. In India, four DAAs, namely sofosbuvir (SOF), daclatasvir (DCV), ledipasvir (LDV) and velpatasvir (VEL), are marketed. Initially, people were treated using SOF in combination with ribavirin with or without pegylated-interferon (Peg-IFN). Thereafter, HCV treatment ...

Phase N/A

Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model

An algorithm was developed using SOF-based regimens to treat all patients (RKD). Genotyping is not recommended for patients without cirrhosis of liver and they are being treated with SOF+DCV for 12-weeks, while genotyping is recommended for patients with cirrhosis of liver (Figure 1). Patients with liver cirrhosis and genotype 3 ...

Phase N/A

Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir/Ribavirin Combination

Aim of the work To determine the benefits of statin use in CHC patients treated with Sofosbuvir/Daclatasvir/Ribavirin through : Primary Outcome: Assessment of therapeutic SVR12 Seconadry Outcome assessment of Chronic hepatitis C(CHC) infection risk on development of metabolic syndrome through assessment of lipid profile , fasting glucose test , HgbA1C ...

Phase

Viral Kinetics Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816

Up to 140 patients with chronic hepatitis C, genotypes 1-4, who were never treated or previously treated but failed a course of therapy with any interferon and ribavirin combination regimen will be eligible to be enrolled into this pilot study to evaluate the combination of sofosbuvir and GS-5816 as a ...

Phase

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

Patients will be selected based on diminished likelihood of receiving a liver from the waitlist within a period during which they would be likely to succumb to severe comorbidities. This will be determined in part through use of a patient's MELD score, listing status, and clinical judgment. To ensure maximal ...

Phase

DAA Therapy in Pediatric Patients With Chronic Hepatitis C

Consecutive chronic hepatitis C (HCV) infected children [age: 12 to <18 years; both treatment-nave (TN) and treatment-experienced, (TE)] are being enrolled. Genotyping is not recommended for non-cirrhotic or TN patients and were treated with SOF+DCV for 12-weeks, while genotyping is recommended for patients with cirrhosis and TE patients. Patients with ...

Phase N/A

Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]

This will be a non-blinded randomized clinical trial with 150 participants randomized at a 1:1:1 allocation ratio to one of three treatment arms. Arm 1: Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180g/weekly) for 4 weeks with a field-based DOT approach Arm 2: Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) ...

Phase